Marinus Pharma (MRNS) Provides Business Update And Reports Third Quarter 2016 Financial Results
11/3/2016 9:07:18 AM
RADNOR, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today provided a business update and announced its financial results for the third quarter ended September 30, 2016.
“We have made significant progress in advancing our status epilepticus program supported by our new intravenous formulation of ganaxolone,” commented Christopher M. Cashman, chief executive officer of Marinus Pharmaceuticals. “With the identification of dose levels of ganaxolone IV that we believe to be safe and efficacious, we are preparing to initiate a Phase 2 study in patients suffering from this life-threatening seizure disorder. Additionally, we are expanding the clinical development of ganaxolone into postpartum depression where there is a significant unmet need and a strong mechanistic rationale for a therapeutic benefit from ganaxolone treatment.”
comments powered by